Date:10/31/2011

sults of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.  Non-GAAP revenuesGAAP revenue$179,445$166,833Foreign currency effects(13,544)(9,736)Non-GAAP revenue - constant currency$165,901$157,097Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring, transformation costs and contingent consideration income$18,665$20,097Foreign currency effects, net of tax(3,213)(3,799)Income tax associated with foreign currency effects9031,112 Non-GAAP net income - constant currency16,35517,410Non-GAAP net income per common share assuming dilutionNon-GAAP net income per common share assuming dilution, adjusted for restructuring, transformation costs and contingent consideration income$0.72$0.80Foreign currency effects after tax per common share assuming dilution($0.09)($0.11)Non-GAAP net income per common share assuming dilution - constant currency$0.63$0.69Reconciliation of Non-GAAP Measures for FY12 and FY11Six Months Ended10/1/201110/2/2010Non-GAAP gross profitGAAP gross profit$178,698$174,217Restructuring and transformation costs1,381-Non-GAAP gross profit$180,079$174,217Non-GAAP R&DGAAP R&D$18,959$15,875Restructuring and transformation costs(1,356)-Non-GAAP R&D$17,603$15,875Non-GAAP S,G&AGAAP S,G&A$118,844$107,144Restructuring and transformation costs(6,129)(2,863)Non-GAAP S,G&A$112,715$104,281Non-GAAP operating expensesGAAP operating expenses$136,223$121,125Restructuring and transformation costs(7,485)(2,863)Contingent consideration income1,5801,894Non-GAAP operating expenses$130,318$120,156Non-GAAP operating income GAAP operating income$42,475$53,092Restructuring and transformation costs8,8652,863Contingent consideration income(1,580)(1,894)Non-GAAP operating income $49,760$54,061Non-GAAP income before taxesGAAP income before taxes$42,705$53,534Restructuring and transformation costs8,8652,863Contingent consideration income(1,580)(1,894)Non-GAAP income before taxes$
'/>"/>

SOURCE Haemonetics Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2012 Earnings Release: October 31, 2011
2. Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011
3. Haemonetics to Present at J.P. Morgan Healthcare Conference
4. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
6. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
7. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
8. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
9. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2011
10. ERT Reports Third Quarter 2011 Operating Results
11. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011